Target Price | $630.05 |
Price | $437.95 |
Potential | 43.86% |
Number of Estimates | 19 |
19 Analysts have issued a price target Synopsys 2026 . The average Synopsys target price is $630.05. This is 43.86% higher than the current stock price. The highest price target is $690.00 57.55% , the lowest is $520.00 18.74% . | |
A rating was issued by 23 analysts: 21 Analysts recommend Synopsys to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Synopsys stock has an average upside potential 2026 of 43.86% . Most analysts recommend the Synopsys stock at Purchase. |
19 Analysts have issued a sales forecast Synopsys 2025 . The average Synopsys sales estimate is $6.8b . This is 11.77% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $6.8b 12.39% , the lowest is $6.7b 11.14% .
This results in the following potential growth metrics:
2024 | $6.1b | 14.95% |
---|---|---|
2025 | $6.8b | 10.71% |
2026 | $7.6b | 12.79% |
2027 | $8.7b | 13.61% |
2028 | $9.9b | 14.51% |
10 Analysts have issued an Synopsys EBITDA forecast 2025. The average Synopsys EBITDA estimate is $2.9b . This is 74.19% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 76.70% , the lowest is $2.9b 72.26% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $1.9b | 12.12% |
---|---|---|
2025 | $2.9b | 50.68% |
2026 | $3.3b | 15.28% |
2027 | $3.9b | 16.59% |
2028 | $4.5b | 16.62% |
2024 | 31.31% | 2.46% |
---|---|---|
2025 | 42.61% | 36.10% |
2026 | 43.55% | 2.21% |
2027 | 44.69% | 2.62% |
2028 | 45.52% | 1.86% |
11 Synopsys Analysts have issued a net profit forecast 2025. The average Synopsys net profit estimate is $1.6b . This is 23.29% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $1.7b 18.64% , the lowest is $1.6b 24.56% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.2b | 83.21% |
---|---|---|
2025 | $1.6b | 28.53% |
2026 | $1.9b | 16.90% |
2027 | $2.3b | 25.00% |
2028 | $2.8b | 20.87% |
2024 | 36.63% | 59.38% |
---|---|---|
2025 | 23.65% | 35.44% |
2026 | 24.51% | 3.64% |
2027 | 26.97% | 10.04% |
2028 | 28.47% | 5.56% |
11 Analysts have issued a Synopsys forecast for earnings per share. The average Synopsys EPS is $10.37 . This is 23.30% lower than earnings per share in the financial year 2024. The highest EPS forecast is $11.00 18.64% , the lowest is $10.20 24.56% .
This results in the following potential growth metrics and future valuations:
2024 | $14.51 | 83.21% |
---|---|---|
2025 | $10.37 | 28.53% |
2026 | $12.12 | 16.88% |
2027 | $15.15 | 25.00% |
2028 | $18.32 | 20.92% |
Current | 32.38 | 50.52% |
---|---|---|
2025 | 42.23 | 30.42% |
2026 | 36.12 | 14.47% |
2027 | 28.90 | 19.99% |
2028 | 23.91 | 17.27% |
Based on analysts' sales estimates for 2025, the Synopsys stock is valued at an EV/Sales of 9.52 and an P/S ratio of 9.99 .
This results in the following potential growth metrics and future valuations:
Current | 10.64 | 27.47% |
---|---|---|
2025 | 9.52 | 10.50% |
2026 | 8.44 | 11.34% |
2027 | 7.43 | 11.98% |
2028 | 6.49 | 12.67% |
Current | 11.16 | 24.39% |
---|---|---|
2025 | 9.99 | 10.53% |
2026 | 8.85 | 11.34% |
2027 | 7.79 | 11.98% |
2028 | 6.81 | 12.67% |
Analyst | Rating | Action | Date |
---|---|---|---|
Needham |
Buy
➜
Buy
|
Unchanged | Feb 27 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 27 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Feb 27 2025 |
Rosenblatt |
Buy
➜
Buy
|
Unchanged | Feb 25 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Feb 24 2025 |
Redburn Atlantic |
➜
Buy
|
Initiated | Jan 13 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jan 13 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Needham:
Buy
➜
Buy
|
Feb 27 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Feb 27 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Feb 27 2025 |
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Feb 25 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Feb 24 2025 |
Initiated
Redburn Atlantic:
➜
Buy
|
Jan 13 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Jan 13 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.